UniPR1331
Based on 1 Customer Validation
UniPR1331 is an orally active 3β-hydroxy-Δ5-choline acid derivative that inhibits Eph-ephrin interactions. UniPR1331 blocks the interaction of VEGFR2 with its natural ligand vascular endothelial growth factor and inhibits subsequent autophosphorylation, signaling, and pro-angiogenic activation of endothelial cells. UniPR1331 exhibits anti-angiogenesis, anti-cancer and anti-inflammation effects. UniPR1331 can be used for the researches of cancer and inflammation, such as glioma and colitis.
For research use only. We do not sell to patients.
- Purity : 99.77%
- CAS No.: 1809170-59-9
- Formula: C35H48N2O4
- Molecular Weight:560.77
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All VEGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
VEGFR2 62.2 μM (Kd) |
EPHA2 3.3 μM (Kd) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HUVEC | IC50 |
2.9 μM
Compound: 10
|
Antiangiogenic activity in HUVEC assessed as inhibition of polygons formation after 15 hrs by microscopic analysis
Antiangiogenic activity in HUVEC assessed as inhibition of polygons formation after 15 hrs by microscopic analysis
|
[PMID: 26363867] |
| PC-3 | IC50 |
9.3 μM
Compound: 10
|
Antagonist activity at EphA2 receptor in human PC3 cells assessed as inhibition of ephrin-A1-induced protein phosphorylation after 20 mins by sandwich ELISA
Antagonist activity at EphA2 receptor in human PC3 cells assessed as inhibition of ephrin-A1-induced protein phosphorylation after 20 mins by sandwich ELISA
|
[PMID: 26363867] |
In Vitro
UniPR1331 (4-40 μM) specifically binds to human VEGFR2 (Kd = 62.2 μM) and EphA2 (Kd = 3.3 μM), and competes with VEGF for VEGFR2 binding (IC50 = 16 μM) and ephrin-A1 for EphA2 binding (IC50 = 4 μM)[1].
UniPR1331 (10-30 μM, 10 mins) inhibits VEGF-induced VEGFR2 phosphorylation (IC50 = 22 μM) in HUVECs[1].
UniPR1331 (10-30 μM, 24-48 h) inhibits VEGF-induced proliferation, migration and endothelial sprout formation in HUVECs[2].
UniPR1331 (3-30 μM, 24 h) maintains cells viability above 90% and inhibits TNFα release in mouse splenic lymphocytes treated with PMA (HY-18739) + Ionomycin (HY-13434)[2].
UniPR1331 inhibits tube formation of human umbilical vein endothelial cells (HUVEC) (IC50 = 2.9 μM) and human brain microvascular endothelial cells (HBMVEC) (IC50 = 3.9 μM)[3].
UniPR1331 (10 μM, 24 h) inhibits ephrin-A1-induced EphA2 phosphorylation in U87MG glioma cells and decreases EphA2 protein expression[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U87MG glioma cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Reduced EphA2 phosphorylation levels.
Reduced EphA2 protein expression.
In Vivo
UniPR1331 (10-25 mg/kg, p.o.) shows anti-inflammation effect in the TNBS-induced colitis model of C57BL/6 mice[2].
UniPR1331 (30 mg/kg, p.o., 5 days a week for 30 days) inhibits tumor growth and prolongs survival in CD1-nu/nu mice with U87MG glioma subcutaneous and intracranial xenografts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TNBS-induced colitis model of C57BL/6 mice[1]
-
Dosage:10 and 25 mg/kg
-
Administration:Intraperitoneally injection, twice a day from 8 h after TNBS-induced colitis, continued for 2 days
-
Result:Improved the Disease Activity Index (DAI, including weight loss, stool consistency, rectal bleeding).
Reduced the colonic macroscopic damage score (MS, decreasing strictures, adhesions, ulcers).
Restored colon length (inhibits colon shortening).
Reduced myeloperoxidase (MPO) activity in colon and lung (decreasing neutrophil infiltration).
Restored the splenic CD4+/CD8+ T cell ratio.
-
Animal Model:CD1-nu/nu mice with U87MG glioma subcutaneous and intracranial xenografts[3]
-
Dosage:30 mg/kg
-
Administration:Orally administration, 5 days a week for 30 days
-
Result:Reduced the final weight of tumor.
Prolonged the time to progression.
Decreased the Ki67 proliferation index.
Chemical Information
-
CAS No. 1809170-59-9
-
Appearance Solid
-
Molecular Weight 560.77
-
Formula C35H48N2O4
-
Color White to light yellow
-
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(N[C@H](C(O)=O)CC3=CNC4=CC=CC=C34)=O)([H])[C@@]5([H])[C@@](CC1)([H])[C@@]6(C(C[C@H](CC6)O)=CC5)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 25 mg/mL (44.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rusnati M, et al. Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin. Cancer Gene Ther. 2022 Jul;29(7):908-917. [Content Brief]
[2]. Giorgio C, et al. UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling. Pharmaceuticals (Basel). 2021 May 24;14(6):502. [Content Brief]
[3]. Festuccia C, et al. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget. 2018 May 11;9(36):24347-24363. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7833 mL | 8.9163 mL | 17.8326 mL | 44.5816 mL |
| 5 mM | 0.3567 mL | 1.7833 mL | 3.5665 mL | 8.9163 mL | |
| 10 mM | 0.1783 mL | 0.8916 mL | 1.7833 mL | 4.4582 mL | |
| 15 mM | 0.1189 mL | 0.5944 mL | 1.1888 mL | 2.9721 mL | |
| 20 mM | 0.0892 mL | 0.4458 mL | 0.8916 mL | 2.2291 mL | |
| 25 mM | 0.0713 mL | 0.3567 mL | 0.7133 mL | 1.7833 mL | |
| 30 mM | 0.0594 mL | 0.2972 mL | 0.5944 mL | 1.4861 mL | |
| 40 mM | 0.0446 mL | 0.2229 mL | 0.4458 mL | 1.1145 mL |